XML 51 R17.htm IDEA: XBRL DOCUMENT
v2.4.0.8

SEGMENT AND GEOGRAPHIC INFORMATION | 9 Months Ended
--- | ---
Sep. 30, 2014
Segment Reporting [Abstract] |
SEGMENT AND GEOGRAPHIC INFORMATION | SEGMENT AND GEOGRAPHIC INFORMATION The Company internally manages and reports the results of its businesses to its chief operating decision maker through five reportable segments. The five reportable segments and a description of their activities are described below:
• | The U.S. Neurosurgery segment sells a full line of products specifically for neurosurgery and critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
• | The U.S. Instruments business sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
• | The U.S. Extremities segment includes the U.S. Extremity reconstruction business, which includes such offerings as skin and wound repair, bone and joint fixation, implants in the upper and lower extremities, bone grafts and nerve and tendon repair.
• | The U.S. Spine and Other segment includes (i) the U.S. Spine business, which focuses on spinal fusion, spinal implants, and deformity correction, together with bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in various types of orthopedic surgical procedures, and (ii) the Private Label business, which sells the Company’s regenerative medicine and other products to strategic partners.
• | The International segment sells similar products to those discussed above, but are managed through the following geographies: (i) Europe, Middle East and Africa, and (ii) Central/South America, Asia-Pacific and Canada.
The Corporate and other category includes: (i) various legal, finance, information systems, executive, and human resource functions, (ii) brand management, (iii) share-based compensation costs, and (iv) costs related to procurement, manufacturing operations and logistics for the Company’s entire organization. The operating results of the various reportable segments as presented are not comparable to one another because: (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the three and nine months ended September 30, 2014 and 2013 are as follows:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2014 |  | 2013 |  | 2014 |  | 2013
|  | (In thousands)
|  |  |  | (As adjusted)* |  |  |  | (As adjusted)*
Segment Net Sales |  |  |  |  |  |  |  |
U.S. Neurosurgery |  | $ | 62,323 |  |  | $ | 45,114 |  |  | $ | 177,265 |  |  | $ | 125,877 |
U.S. Instruments |  | 39,853 |  |  | 43,004 |  |  | 116,078 |  |  | 121,900 |
U.S. Extremities |  | 36,746 |  |  | 31,831 |  |  | 103,083 |  |  | 93,802 |
U.S. Spine and Other |  | 42,015 |  |  | 47,408 |  |  | 128,168 |  |  | 134,889 |
International |  | 48,782 |  |  | 45,889 |  |  | 151,535 |  |  | 138,977 |
Total revenues |  | $ | 229,719 |  |  | $ | 213,246 |  |  | $ | 676,129 |  |  | $ | 615,445 |
Segment Profit |  |  |  |  |  |  |  |
U.S. Neurosurgery |  | $ | 35,889 |  |  | $ | 23,080 |  |  | $ | 94,247 |  |  | $ | 59,770 |
U.S. Instruments |  | 12,416 |  |  | 13,713 |  |  | 34,728 |  |  | 35,963 |
U.S. Extremities |  | 14,983 |  |  | 13,117 |  |  | 40,907 |  |  | 34,613 |
U.S. Spine and Other |  | 13,108 |  |  | (31,043 | ) |  | 39,801 |  |  | (4,844 | )
International |  | 15,170 |  |  | 14,693 |  |  | 49,549 |  |  | 41,697 |
Segment profit |  | 91,566 |  |  | 33,560 |  |  | 259,232 |  |  | 167,199 |
Amortization |  | (2,995 | ) |  | (3,036) |  |  | (9,013) |  |  | (9,660) |
Corporate and other |  | (70,844 | ) |  | (61,665 | ) |  | (211,362 | ) |  | (185,314 | )
Operating income (loss) |  | $ | 17,727 |  |  | $ | (31,141 | ) |  | $ | 38,857 |  |  | $ | (27,775 | )
* See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax. Certain 2013 segment revenues and the related impact on segment profit above have been reclassified in order to conform with the current year's presentation. Revenue by major product category consisted of the following:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2014 |  | 2013 |  | 2014 |  | 2013
| (In thousands)
Orthopedics | $ | 91,650 |  |  | $ | 92,125 |  |  | $ | 271,958 |  |  | $ | 271,862 |
Neurosurgery | 92,089 |  |  | 72,639 |  |  | 269,717 |  |  | 204,283 |
Instruments | 45,980 |  |  | 48,482 |  |  | 134,454 |  |  | 139,300 |
Total Revenues | $ | 229,719 |  |  | $ | 213,246 |  |  | $ | 676,129 |  |  | $ | 615,445 |
The Company attributes revenues to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments that are generated from non-U.S. customers and therefore are included in Europe and the Rest of World revenues below. Total revenue by major geographic area consisted of the following:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2014 |  | 2013 |  | 2014 |  | 2013
| (In thousands)
United States | $ | 180,101 |  |  | $ | 166,555 |  |  | $ | 522,288 |  |  | $ | 473,740 |
Europe | 23,850 |  |  | 21,543 |  |  | 75,026 |  |  | 68,936 |
Rest of World | 25,768 |  |  | 25,148 |  |  | 78,815 |  |  | 72,769 |
Total Revenues | $ | 229,719 |  |  | $ | 213,246 |  |  | $ | 676,129 |  |  | $ | 615,445 |

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration